Abstracts tagged "longitudinal studies"

Abstract Number: 3146 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life in Adults with JIA – a 30 Year Longitudinal Study
Anita Tollisen^1,2,3, Anne Marit Selvaag¹, Hanne A. Aulie¹, Anners Lerdal^4,5 and Berit Flato^1,2, ¹Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ²Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ³Department of Medicine, Lovisenberg Diakonale Hospital, Oslo, Oslo, Norway, ⁴Faculty of Medicine, Institute of Health and Society, University of Oslo, Oslo, Norway, ⁵Lovisenberg Diakonale Hospital, Oslo, Oslo, Norway
Background/Purpose: Improvement of health-related quality of life (HRQOL) is a central aim in treatment of patients with JIA. The primary aim of the study is…
Abstract Number: 31 • 2015 ACR/ARHP Annual Meeting
Risk of Chronic Obstructive Pulmonary Disease in Rheumatoid Arthritis: A Population Based Cohort Study
Katherine McGuire¹, J Antonio Avina-Zubieta², Eric C. Sayre¹, JM Esdaile³ and Diane Lacaille⁴, ¹Arthritis Research Canada, Richmond, BC, Canada, ²Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ⁴Arthritis Research Centre, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: A link between chronic obstructive pulmonary disease (COPD) and inflammation has been established in a number of studies. This raises the question of whether…
Abstract Number: 392 • 2015 ACR/ARHP Annual Meeting
From Childhood to Adulthood: Longitudinal Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Lily Siok Hoon Lim^1,2,3,4, Eleanor Pullenayegum⁵, Lillian Lim⁶, Dafna Gladman⁷, Brian Feldman⁸ and Earl Silverman⁹, ¹Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Rheumatology, SickKids, Toronto, ON, Canada, ³Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB, Canada, ⁵Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Outcomes of patients with cSLE over time and into adulthood are poorly understood. There has been no information about the longitudinal trajectory of organ…
Abstract Number: 395 • 2015 ACR/ARHP Annual Meeting
Depression Risk Among Adults with Childhood- and Adult-Onset Systemic Lupus Erythematosus: 11 Years of Follow-up
Erica F. Lawson¹, Andrea Knight², Laura Trupin³, Patricia P. Katz³ and Edward H. Yelin⁴, ¹Pediatrics/Rheumatology, UC San Francisco, San Francisco, CA, ²Pediatrics/Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, UC San Francisco, San Francisco, CA
Background/Purpose: Neuropsychiatric syndromes are prevalent in childhood-onset systemic lupus erythematosus (cSLE), but the long-term risk of depression in adults with cSLE is unknown. We compared…
Abstract Number: 668 • 2015 ACR/ARHP Annual Meeting
Pasdas, Cpdai and MDA Evolution in the First 6 Months after Diagnosis of Early Psoriatic Arthritis Patients: Results of the Depar Study
Jolanda Luime¹, Ilja Tchetverikov², Marijn Vis³, Cathelyne Appels⁴, Wiebo van der Graaff⁵, Josien Veris⁶, Andreas Gerards⁷, Hans van Groenendaal⁸, Mark Kok⁹, Lindy-Anne Korswagen¹⁰, Cor Stolk¹¹ and Cicero, ¹Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ²Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ³Rheumatology, ErasmusMC, Rotterdam, Netherlands, ⁴Rheumatology, Amphia Hospital, Breda, Netherlands, ⁵Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁶Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands, ⁷Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Maasstadweg 21, Maasstad Ziekenhuis, Rotterdam, Netherlands, ¹⁰Rheumatology, Sint Fransicus Gasthuis, Rotterdam, Netherlands, ¹¹-, Patient Partner, Bunnink, Netherlands
Background/Purpose: Several disease activity measures were developed for use in psoriatic arthritis (PsA) . Little data is available on their performance in usual care. This…
Abstract Number: 709 • 2015 ACR/ARHP Annual Meeting
Progression of Patients with Non-Radiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study
Runsheng Wang¹, Sherine Gabriel² and Michael M. Ward¹, ¹NIH/NIAMS, Bethesda, MD, ²Division of Rheumatology; Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The long-term outcome of patients with non-radiographic axial spondyloarthritis (nr-axSpA) is unclear, particularly whether few or most progress to ankylosing spondylitis (AS). Our objective…
Abstract Number: 712 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Anti-TNF Treatment in a Longitudinally Followed Ankylosing Spondylitis (AS) Cohort
Mary Gibson¹, MinJae Lee², Michael M. Ward³, Lianne S. Gensler⁴, Matthew A. Brown⁵, Shervin Assassi⁶, Colton Pence¹, Laura A. Diekman⁷, Mohammad H. Rahbar⁸, Michael H. Weisman⁹ and John D. Reveille¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁷Rheumatology, University of Texas Medical School, Houston, TX, ⁸The University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: TNF-α inhibitor therapy is recommended by ASAS/EULAR guidelines for ankylosing spondylitis (AS) patients with moderate-to-high disease activity despite inadequate response to NSAIDs in addition…
Abstract Number: 716 • 2015 ACR/ARHP Annual Meeting
Urinary Proteomics Identifies Three Novel Biomarkers for Lupus Nephritis Activity: Retinol Binding Protein, Alpha-1-Antichymotrysin and Haptoglobin
Amita Aggarwal¹, Sudhir sinha², Ranjan Gupta³, Liza Rajasekhar⁴, Akhilesh Yadav³, Ramnath Misra¹ and Virsingh Negi⁵, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Biochemistry, CSIR-central drug research institute, Lucknow, India, ³Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁴Department of Rheumatology, Nizam Institute of Medical Sciences, Hyderabad, India, ⁵Department of Clinical Immunology, JIPMER, Puducherry, India
Background/Purpose: Urinary biomarkers have a potential for identification, follow-up and assessment of response to treatment in patients with lupus nephritis. Urinary proteomics can help in…
Abstract Number: 849 • 2015 ACR/ARHP Annual Meeting
A Computational Tool for Individualized Prognosis of Percent of Predicted Forced Vital Capacity Trajectories in Systemic Sclerosis
Peter Schulam¹, Colin Ligon², Robert Wise³, Laura K. Hummers⁴, Fredrick M. Wigley⁵ and Suchi Saria^1,6, ¹Department of Computer Science, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Departments of Biostatistics, and Health Policy and Management, Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Interstitial lung disease (ILD) is a common cause of mortality in systemic sclerosis (Ssc). Decreased forced vital capacity (FVC) in Ssc-ILD is associated with…
Abstract Number: 1645 • 2015 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Ketti Terry⁴, Kenneth Kwok⁵, Irina Lazariciu⁶, Chudy Nduaka⁷, Carol A. Connell⁴, Ryan DeMasi⁵ and Lisy Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Quintiles, Saint-Laurent, QC, Canada, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report tofacitinib safety, tolerability, and clinical response over 84 months…
Abstract Number: 1708 • 2015 ACR/ARHP Annual Meeting
Predictors of Depression Severity in Ankylosing Spondylitis
Mark Hwang¹, MinJae Lee², Michael M. Ward³, Lianne S. Gensler⁴, Matthew A. Brown⁵, Shervin Assassi⁶, Laura A. Diekman⁷, Mohammad H. Rahbar⁸, Michael H. Weisman⁹ and John D. Reveille¹⁰, ¹Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁷Rheumatology, University of Texas Medical School, Houston, TX, ⁸The University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Depression is a known comorbidity of ankylosing spondylitis (AS) with over one-third of AS patients affected and increased depression-rate ratio compared to the general…
Abstract Number: 2054 • 2014 ACR/ARHP Annual Meeting
Physical and Mental Functioning in Patients with Established Rheumatoid Arthritis over an 11-Year Follow-up Period: The Role of Specific Comorbidities
Joëlle van den Hoek¹, Leo D. Roorda², Hendriek C. Boshuizen³, Gerard J. Tijhuis⁴, Trudi van den Bos⁵ and Joost Dekker⁶, ¹Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, ²Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ³National Institute of Public Health and the Environment, Bilthoven, Netherlands, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Social Medicine, Academic Medical Center, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose Comorbidity in patients with Rheumatoid Arthritis (RA) is highly prevalent and plays an important role in determining RA related outcomes. Several studies have reported…
Abstract Number: 2047 • 2014 ACR/ARHP Annual Meeting
No Association of Serum Uric Acid with Hip Fracture Risk in Older Men and Women from the Framingham Original Cohort
Shivani Sahni¹, Kelsey Mangano², Katherine Tucker³, Caroline Fox⁴, Douglas P. Kiel⁵, Xiaochun Zhang⁶ and Marian T. Hannan¹, ¹Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Clinical Laboratory & Nutritional Sciences, Center for Population Health & Health Disparities, University of Massachusetts, Lowell, MA, ⁴Institute of Genetics and Biophysics, NHLBI's Framingham Heart Study and Center for Population Studies, Framingham, MA, ⁵Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA
Background/Purpose: Serum uric acid (UA) has been linked with fractures in older men. Three different studies in older men showed conflicting results. The objective…
Abstract Number: 1286 • 2014 ACR/ARHP Annual Meeting
The Natural Course of Physical Function in People with Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Britt Elin Øiestad¹, Daniel White², Ross Booton³, Jingbo Niu³, Yuqing Zhang⁴, James C. Torner⁵, Cora E. Lewis⁶, Michael C. Nevitt⁷, Michael P. Lavalley⁸ and David T. Felson⁹, ¹Department of Orthopedics, Oslo University Hospital, 0407 Oslo, Norway, ²Clinical Epidemiology Training, Boston Univ School of Med, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Epidemiology, University of Iowa, Iowa City, Iowa City, IA, ⁶Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL, ⁷Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ⁸Biostatistics, Boston University, Boston, MA, ⁹Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Longitudinal studies of people with knee osteoarthritis (OA) have reported stable or improved physical function, contrary to the progressive degenerative nature of OA. The…
Abstract Number: 1062 • 2014 ACR/ARHP Annual Meeting
Impact of Obesity on 1 Year Outcomes: Results from the Meteor Foundation International Rheumatoid Arthritis Cohort
Christopher Sparks¹, Robert Moots¹, Eftychia Psarelli², Tom Huizinga³ and Nicola Goodson¹, ¹Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, ²Cancer Research UK Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Increased adiposity is associated with increased production of pro-inflammatory adipokines and raised inflammatory markers. As a result, standard disease activity scores (DAS) may be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].